Brentuximab Vedotin
2016-0854
Phase 1 small_molecule terminated
Quick answer
Brentuximab Vedotin for Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic is a Phase 1 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated